KEY POINTS
- This preclinical investigation tested DNA vaccines designed to stimulate endogenous antibodies against PD-1 and CTLA-4, administered alone or with radiation therapy in syngeneic B16 and B78 murine melanoma models. Vaccines were delivered by intramuscular or intratumoral electroporation using three to four weekly injections. Radiotherapy was delivered as 8 Gy in three consecutive daily fractions to selected tumors, with antibody production, tumor growth, immune infiltration, and survival assessed.
- The vaccines successfully induced endogenous checkpoint-targeting antibodies. Repeated CTLA-4 and PD-1 vaccination produced serum antibodies in the μg/mL range, with concentrations typically peaking approximately one week after the final injection. CTLA-4 vaccine-derived antibodies demonstrated target binding in an experimental T-cell assay. However, vaccine-generated concentrations were lower than those achieved with standard exogenous checkpoint antibodies, and neither single vaccination nor dual vaccination alone significantly suppressed B16 melanoma growth.
- Combining CTLA-4 vaccination with local RT significantly improved tumor growth suppression. In established B16 tumors, RT plus CTLA-4 vaccination produced greater growth inhibition than either intervention alone (p<0.001). Treated tumors showed increased CD8-positive tumor-infiltrating lymphocytes and granzyme B expression, alongside trends toward reduced suppressive myeloid-cell and macrophage populations. Despite these immune changes, all mice eventually developed progressive disease, indicating that the antitumor effect was not durable.
- Systemic antitumor responses were limited in a bilateral B16 melanoma model. When only one tumor was irradiated, dual PD-1/CTLA-4 vaccination plus RT increased CD8-positive immune infiltration in both irradiated and distant tumors and reduced tumor PD-L1 expression. However, delayed growth of both tumors suggestive of an abscopal response was observed in only one of seven mice receiving the combination. Most animals ultimately experienced progression, so the findings do not establish reproducible systemic tumor control.
- A less immunogenic B78 melanoma model demonstrated additional resistance. Dual vaccination plus local RT significantly suppressed the irradiated tumor (p<0.001) but did not significantly inhibit the distant nonirradiated tumor or prolong survival. Intratumoral vaccination produced a greater numerical delay in distant tumor growth than intramuscular vaccination, but this difference remained nonsignificant (p=0.10). Antibody titers were comparable between injection routes.
- The immune response was accompanied by potential compensatory suppression. Although combined treatment increased CD8-positive tumor infiltration, progressing tumors also showed increased regulatory T-cell infiltration, potentially contributing to eventual resistance. The study did not establish the independent causal contribution of each immune-cell population or whether the observed immune changes would occur in human tumors.
- No clinical efficacy, optimal dosing, or comprehensive immunotoxicity data are available. These results come exclusively from mouse melanoma experiments with limited group sizes, nonclinical vaccine constructs, and an irradiation schedule selected for experimental immune stimulation. DNA vaccine-induced checkpoint blockade also differs from licensed monoclonal antibody therapy in pharmacokinetics, reversibility, and immune effects. Additional preclinical work is required before human treatment development.
CLINICAL TAKEAWAY
DNA-based vaccines can induce endogenous antibodies against PD-1 and CTLA-4 and enhance local radiation-associated immune responses in murine melanoma models. However, durable systemic tumor control was uncommon, with only limited evidence of abscopal responses and no demonstrated survival benefit in the more resistant B78 model. The findings remain an early preclinical proof of concept rather than evidence supporting clinical substitution for conventional checkpoint inhibitors.